Lilly Bullish On Diabetes/Oncology Products; Analysts Skeptical
This article was originally published in The Pink Sheet Daily
Executive Summary
The Indianapolis-based big pharma touted the value of its late-stage pipeline at an analyst meeting on Oct. 3, particularly its diabetes and oncology franchises, even though they face tough competition and have encountered some setbacks.
You may also be interested in...
Emerging Markets Earnings Roundup: Eli Lilly, Roche (Part 4)
Eli Lilly says emerging markets remain a growing focus as it navigates sliding sales for key products in developed markets due to patent expirations. Roche looks to patient access programs again as biosimilar competition threats grow.
South Korea’s Hanmi Opens Global Trials Of Monthly Dose GLP-1 Biosimilar
Hanmi hopes to differentiate its type 2 diabetes Byetta biosimilar with once-a-month administration.
Lilly Gets Ready To Compete With Its Late-Stage Diabetes Pipeline
The Indianapolis-based pharma highlighted the Phase III results from two of its most promising pipeline candidates at ADA. The company is preparing to have four new diabetes drugs on the market by 2016, including two basal insulins, a GLP-1 agonist and a SGLT-2 inhibitor.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: